5 active not recruiting, 4 completed, 2 recruiting. 7 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 2, Recruiting 1 |
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Selumetinib Sulfate: new trials by email Literature Review of Selumetinib Sulfate trials Research Report on Selumetinib Sulfate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 165 | 2023-04-25 | 2026-10-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-11-02 |
| A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment - Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 300 | 2021-02-16 | 2026-07-02 |
| A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma Biospecimen Collection, Carboplatin, Echocardiography Test - Low Grade Astrocytoma, Low Grade Glioma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 170 | 2020-01-31 | 2026-10-29 |
| A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment - Low Grade Glioma, Neurofibromatosis Type 1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 165 | 2020-01-15 | 2026-08-13 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2017-10-30 | 2025-02-05 |
| Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Laboratory Biomarker Analysis, Selumetinib Sulfate - Cutaneous Neurofibroma, Neurofibromatosis Type 1 | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2017-08-26 | 2023-12-06 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations Laboratory Biomarker Analysis, Selumetinib Sulfate - KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2017-07-21 | 2021-02-09 |
| Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis - Metastatic Melanoma, Refractory Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2011-05-25 | 2026-09-10 |
| Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib - Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2007-12-17 | 2020-12-03 |
Central Nervous System Neoplasms (2) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Neuroblastoma (2) · Neurofibromatosis 1 (2) · Ovarian Neoplasms (2) · Cystadenocarcinoma, Serous (1) · Ependymoma (1) · Glioma (1) · Hepatoblastoma (1) · Histiocytic Sarcoma (1) · Histiocytosis, Langerhans-Cell (1) · Medulloblastoma (1) · Melanoma (1)
National Cancer Institute (NCI) (11)
United States (11) · Puerto Rico (6) · Canada (4) · Australia (1)
Brian A Costello (1) · Bruce R Korf (1) · Carl E Allen (1) · Daniel C Bowers (1) · Donald W Parsons (1) · James M Ford (1) · Jason R Fangusaro (1) · John H Farley (1) · Peter M de Blank (1) · Shannon N Westin (1) · Udo Rudloff (1)
PMID 33395032, PMID 23261356, PMID 32597469, PMID 33405090, PMID 33591402, PMID 35353553, PMID 35363510, PMID 38270822, PMID 38907342, PMID 40009403, PMID 40685312, PMID 41166674, PMID 42686334
U10CA180886 (5), U10CA180868 (2), P30CA013148 (1), P30CA015083 (1), U01CA069912 (1), U10CA027469 (1), U10CA180820 (1), UM1CA186686 (1), ZIABC011078 (1)